1. Medtech Insight
  2. >>Business
  3. >>Deals

Dealmaking: Q3 Roundup Shows Deal Values Jump From Prior Quarter

A look at M&A and alliance activity across the medical device and in vitro diagnostics industries, July-September 2020

 
• By Deanna Kamienski and Maureen Riordan

Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

M and A diagram, Businessman hand touching M&A (Merger and Acquisition) sign on virtual screen

Featuring 24 completed device M&A transactions, half of which had disclosed values together totaling $17.9bn, the third quarter showed an exponential increase in deal value (and deal volume also notably rose) from Q2’s $159m (for five completed deals; see Exhibit 1). At the top, making up 92% of the Q3 total was Siemens Healthineers AG’s definitive agreement to acquire public radiotherapy developer Varian Medical Systems, Inc.. in an all-cash transaction valued at $16.4bn. ([A#MT142548])

Even without this transaction, the Q3 deal value, at $1.5bn, was still almost 10 times more than the previous quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Luna Health Raises $23.6M, Furthering Launch Of ‘World’s Smallest’ Insulin Pump

 
• By Natasha Barrow

Luna Health has raised $23.6m in Series A funding to support regulatory submissions, clinical studies and manufacturing for its insulin patch pump.

Industry Experts Expect AI-Driven Medtech M&A To Continue In 2025

 
• By Marion Webb

AI-driven medtech M&A slowed slightly in volume but tripled in value in early 2025, with buyers focusing on AI-driven diagnostics, surgical tech and analytics. Industry experts expect continued high-value deals as firms defend market share and pursue workflow-enhancing AI.

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 
• By Natasha Barrow

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

Exact Sciences Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 
• By Natasha Barrow

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

More from Business

Breathing Easy: Freespira Works To Expand Access To Panic And PTSD Treatment

 
• By Elizabeth Orr

Freespira’s device has been FDA-approved to treat panic disorders and PTSD. CEO Joe Perekupka told Medtech Insight the company’s innovative approach includes patient coaching, insurance partnerships to identify potential users, and lobbying for broader insurance coverage for digital therapeutics.

Nyxoah Launches FDA-Cleared Genio System For OSA As Rival Inspire Files Patent Suit

 
• By Marion Webb

After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.

Inaccurate Carbon Dioxide Readings Prompt Class I Recall Of Draeger Ventilation Filters

 
• By Brian Bossetta

Draeger Medical has recalled certain SafeStar and TwinStar ventilation filters after reports of serious injuries caused by misleading carbon dioxide readings.